Vaxart, Inc.

55 articles with Vaxart, Inc.

• Vaxart to Participate at the H.C. Wainwright BioConnect Virtual Conference

  1/4/2022

  Vaxart, Inc. announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will participate in a virtual fireside chat at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022.

• Vaxart to Test Cross-Reactivity of its COVID-19 Oral Tablet Vaccine Against Omicron

  12/16/2021

  Vaxart, Inc. (NASDAQ: VXRT) said today it plans to test the cross-reactivity of its oral tablet COVID-19 vaccine candidate against the Omicron SARS-CoV-2 variant in two different studies expected to begin next month.

• Vaxart Announces Acquisition of Second GMP Manufacturing FacilityPurchase expected to give Vaxart greater control over manufacturing schedules

  12/1/2021

  Vaxart, Inc. (NASDAQ: VXRT) has entered into an agreement with Kindred Bioscience, Inc. (“KindredBio”) for the purchase of KindredBio’s manufacturing equipment and sublease of its GMP (Good Manufacturing Practices) manufacturing facility in Burlingame, California, giving Vaxart control of its second GMP manufacturing facility.

• Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2021 on November 30, 2021 

  11/23/2021

  Vaxart, Inc. (NASDAQ: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congress West Coast 2021 in San Diego on Tuesday, November 30, 2021 at 2:40 p.m. PT.

• 

  New Hope for Oral Flu Vaccine as Prime Season Descends

  11/19/2021

  ​Scientists from Stanford University investigated the effectiveness of an oral tablet flu vaccine called VXA-A1.1 by Vaxart, which uses cellular correlates of protection. 

• Stanford Scientists First To Identify New Cellular Correlates of Protection Against Influenza for an Oral Flu Vaccine Developed by Vaxart

  11/18/2021

  A new Stanford study published in Cell Host and Microbe has demonstrated that VXA-A1.1, an investigational oral tablet flu vaccine under development by Vaxart, Inc., had cellular correlates of protection against influenza infection.1

• Vaxart Announces Publication of Complete Data from Preclinical COVID-19 Oral Vaccine Hamster Challenge Study in Journal of Infectious Diseases

  11/16/2021

  Vaxart, Inc. (NASDAQ: VXRT) announced today the Journal of Infectious Diseases has published complete data from Vaxart’s preclinical Hamster Challenge Study.

• Vaxart to Participate at Upcoming Conferences - Nov 11, 2021

  11/11/2021

  Vaxart, Inc. announced that Andrei Floroiu, President and CEO, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will be participating in virtual fireside chats at the following conferences.

• Vaxart Provides Business Update and Reports Third Quarter 2021 Financial Results

  11/4/2021

  Vaxart, Inc. issued its business update for the third quarter of 2021, reporting strong forward momentum in developing its oral vaccine platform consisting of tablet vaccines that it believes may revolutionize public health.

• Vaxart Doses First Subject in Phase II COVID-19 Oral Tablet Vaccine Clinical Trial

  10/26/2021

  Vaxart, Inc. today announced that it has dosed the first subject in its Phase II COVID-19 oral tablet vaccine clinical trial, the only Phase II trial of an oral tablet COVID-19 vaccine underway in the world.

• Vaxart Begins Recruiting in Global Phase II COVID-19 Oral Tablet Vaccine Clinical Trial

  10/6/2021

   Vaxart, Inc. (NASDAQ: VXRT) today announced that it has begun recruiting subjects for its Phase II COVID-19 oral tablet vaccine clinic

• Vaxart Appoints Dr. James F. Cummings as Chief Medical Officer

  9/27/2021

  Vaxart, Inc. (NASDAQ: VXRT), today announced the appointment of James F. Cummings, M.D., as the Company's Chief Medical Officer (CMO). Dr. Cummings is a Board-Certified Infectious Diseases Physician with extensive experience in vaccine, drug and diagnostics development.

• Vaxart To Present at Upcoming Vaccine Conferences

  9/22/2021

  Vaxart, Inc. (NASDAQ: VXRT), today announced that one of the company's senior scientists, Susan Johnson PhD, will present at both ID Week 2021 and the 15 th Vaccine Congress.

• Vaxart  Announces Creation of Manufacturing and Quality Advisory Board

  9/21/2021

  Vaxart, Inc., announced that it has formed a Manufacturing and Quality Advisory Board.

• Vaxart to Present at the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30

  9/20/2021

  Vaxart, Inc. (NASDAQ: VXRT) today announced that Chief Executive Officer Andrei Floroiu and Chief Scientific Officer Dr. Sean Tucker will present at the 2021 Cantor Virtual Global Healthcare Conference at 10:40 a.m. ET on Thursday, September 30, 2021. 

• Vaxart to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/7/2021

  Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and CEO, and Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the H.C. Wainwright 23rd Annual Global Investor Conference taking place Sept. 13-15, 2021.

• 

  BioSpace Movers & Shakers, Aug. 27

  8/27/2021

  Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.

• Vaxart Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D., Joins Board of Directors

  8/23/2021

  Vaxart, Inc. (NASDAQ: VXRT) today announced the addition of Julie M. Cherrington, Ph.D., to the company's board of directors

• Vaxart Announces Creation of New Scientific and Clinical Advisory Board

  8/19/2021

  Vaxart, Inc. (NASDAQ: VXRT), today announced the creation of an eight-member Scientific and Clinical Advisory Board. 

• 

  Clinical Catch-Up: August 2-6

  8/9/2021

  It was a busy week for clinical trial announcements. Take a look.